SCHEMBL13617194

SCHEMBL13617194

CN(C)C(=O)CCCCC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
CHRNB2 P17787 1/20 0.45
CHRNB4 P30926 1/20 0.45
CHRNA4 P43681 1/20 0.45
HTT P42858 1/20 0.35
LMNA P02545 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
KDM4A O75164 7/20 0.32
KDM4C Q9H3R0 7/20 0.32
KDM5A P29375 1/20 0.32
KDM7A Q6ZMT4 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
FFAR1 O14842 1/20 0.32
CPT2 P23786 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TBXAS1 P24557 1/20 0.32
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8567763 0.98 ALDH1A1 (0.52) ALDH1A1CHRNB2CHRNB4CHRNA4HTT
SCHEMBL13334811 0.93 ALDH1A1 (0.56) ALDH1A1CHRNB2CHRNB4CHRNA4HTT
SCHEMBL8971741 0.84 GPR84 (0.55) ALDH1A1FFAR1TDP1
SCHEMBL8570761 0.83 ALDH1A1 (0.48) ALDH1A1CHRNB2CHRNB4CHRNA4PHF8
SCHEMBL19756278 0.83 ALDH1A1 (0.35) ALDH1A1CHRNB2CHRNB4CHRNA4LMNA
SCHEMBL10389155 0.83 ALOX5 (0.44) ALDH1A1HDAC1HDAC2HDAC6KDM4A
SCHEMBL10388290 0.83 ALOX5 (0.44) ALDH1A1HDAC1HDAC2HDAC6KDM4A
SCHEMBL131476 0.83 ALDH1A1 (0.74) ALDH1A1CHRNB2CHRNB4CHRNA4HTT
SCHEMBL19756263 0.81 HDAC1 (0.35) ALDH1A1LMNAHDAC1HDAC2HDAC6
SCHEMBL6379472 0.81 ALDH1A1 (0.48) ALDH1A1CHRNB2CHRNB4CHRNA4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. 2019-05-23 US disclosed
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF MALT1, MYLK2, FKBP1B ALDH1A1 2805/4885CHRNB2 3201/4885CHRNB4 4211/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 ALDH1A1 1604/4885CHRNB2 4873/4885CHRNB4 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.